# A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%

> **NCT00151541** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 301 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Dapsone Topical Gel + adapalene gel 0.1%
- **DRUG:** Dapsone Topical Gel + benzoyl peroxide gel 4%
- **DRUG:** Dapsone Topical Gel + vehicle control

## Key facts

- **NCT ID:** NCT00151541
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2011-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151541, "A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00151541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*